

Table 8 Discounted cost-effectiveness^a of PCV-13 (10 cohorts vaccinated over the period 2014–2023) compared with no vaccination for the government and society

	Government	Society
Net cost of PCV-13 introduction (million US\$)	573.31	466.53
Cost of vaccine introduction	618.85	618.85
Health service costs avoided	45.54	152.32
DALYs averted (000s)	303.34	303.34
Years lived with disability averted	7.88	7.88
Years of life lost averted	295.46	295.46
US\$ per DALY averted	1 890	1 538
Cost-effectiveness threshold (US\$)		
1 × GDP per capita (2012) ^b	4 526	4 526
3 × GDP per capita (2012) ^c	13 578	13 578

DALY = disability-adjusted life year; GDP = gross domestic product.

^aCosts and DALYs were discounted at 3% a year.

^bWorld Health Organization threshold for highly cost-effective.

^cWorld Health Organization threshold for cost-effective.